Chong Kun Dang Pharmaceutical

This large Phase 3 trial is testing whether a new combination drug called CKD-202A works better than a common standard medication (valsartan) at lowering high blood pressure. It will involve 324 adults with essential hypertension. The study is designed to see if the new drug prov…

This is the first human study of an experimental drug called CKD-512. It aims to find a safe dose and see if the drug, given alone or with an existing immunotherapy (pembrolizumab), can help control advanced solid tumors. The study is for people whose cancer has continued to grow…

This early-stage study aims to see if a new, potentially lower-cost version of the psoriasis drug Skyrizi (called CKD-704) behaves similarly in the body. It will compare how healthy adults process a single dose of the new drug versus the original versions from the US and Europe. …

This early-stage study aims to understand how a new potential drug for atopic dermatitis (eczema), called CKD-706, behaves in the body compared to two versions of an existing drug, Dupixent. It involves 519 healthy adult volunteers who will receive a single dose. Researchers will…